Cepi, which is funded by several countries and philanthropic donors, was set up three years ago in the wake of the Ebola epidemic, which killed 11,000 people. Despite an Ebola vaccine (later shown to be almost 100% effective) having been in development for a decade, it was not deployed until more than a year into the epidemic.
This time the aim is to have a viable vaccine in production within as little as 16 weeks – although testing for safety and efficacy will take longer.
One advantage is that the new coronavirus, 2019-nCoV, belongs to the same family as the severe acute respiratory syndrome (Sars), for which a vaccine was developed following the 2002 outbreak. “Certainly that information will give us a head start,” said Prof Brendan Wren, dean of the faculty of infectious and tropical diseases at London School of Hygiene and Tropical Medicine (LSHTM).